{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:13:55Z","timestamp":1794244435159,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1188693"],"award-info":[{"award-number":["OPP1188693"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HPV infection is the primary cause of cervical cancer, a leading cause of cancer among women in Kenya and many sub-Saharan African countries. High coverage of HPV vaccination is a World Health Organization priority to eliminate cervical cancer globally, but vaccine supply and logistics limit widespread implementation of the current two or three dose HPV vaccine schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We are conducting an individual randomized controlled trial to evaluate whether a single dose of the bivalent (HPV 16\/18) or nonavalent (HPV 16\/18\/31\/33\/45\/52\/58\/6\/11) HPV vaccine prevents persistent HPV infection, a surrogate marker for precancerous lesions and cervical cancer. The primary objective is to compare the efficacy of immediate, single-dose bivalent or nonavalent vaccination with delayed HPV vaccination. Kenyan women age 15\u201320\u2009years old are randomized to immediate bivalent HPV and delayed meningococcal vaccine (group 1), immediate nonavalent HPV vaccine and delayed meningococcal vaccine (group 2), or immediate meningococcal vaccine and delayed HPV vaccine (group 3) with 36\u2009months of follow-up. The primary outcome is persistent vaccine-type HPV infection by month 18 and by month 36 for the final durability outcome. The secondary objectives include to (1) evaluate non-inferiority of antibody titers among girls and adolescents (age 9 to 14\u2009years) from another Tanzanian study, the DoRIS Study (NCT02834637), compared to KEN SHE Study participants; (2) assess the memory B cell immune response at months 36 and 37; and (3) estimate cost-effectiveness using the trial results and health economic models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will evaluate single-dose HPV vaccine efficacy in Africa and has the potential to guide public health policy and increase HPV vaccine coverage. The secondary aims will assess generalizability of the trial results by evaluating immunobridging from younger ages, durability of the immune response, and the long-term health benefits and cost of single-dose HPV vaccine delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03675256\">NCT03675256<\/jats:ext-link>\n                      . Registered on September 18, 2018\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-021-05608-8","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T09:06:43Z","timestamp":1632733603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-6003","authenticated-orcid":false,"given":"Ruanne V.","family":"Barnabas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricianah","family":"Onono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Cherne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Leingang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rechkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Celum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the KEN SHE Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"5608_CR1","unstructured":"Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, G\u00f3mez D, et al. Human papillomavirus and related diseases in Kenya: Summary Report Barcelona; 2017."},{"issue":"8","key":"5608_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1405044.","journal-title":"N Engl J Med"},{"issue":"21","key":"5608_CR3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645\u201351. https:\/\/doi.org\/10.1056\/NEJMoa020586.","journal-title":"N Engl J Med"},{"key":"5608_CR4","volume-title":"Global HPV vaccine introduction overview","author":"PATH","year":"2020","unstructured":"PATH. Global HPV vaccine introduction overview. 2020."},{"key":"5608_CR5","volume-title":"Human papillomavirus vaccine: supply and demand update","author":"UNICEF","year":"2020","unstructured":"UNICEF. Human papillomavirus vaccine: supply and demand update. 2020."},{"issue":"10197","key":"5608_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, Benard E, Perez N, Brisson M, HPV. Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509.","journal-title":"Lancet"},{"key":"5608_CR7","unstructured":"Gavi. Human papillomavirus vaccine support 2020 [Available from: https:\/\/www.gavi.org\/types-support\/vaccine-support\/human-papillomavirus."},{"key":"5608_CR8","unstructured":"Kreimer AR. Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines ClinicalTrials.gov: U. S. National Library of Medicine; 2017 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03180034]. Accessed 27 Feb 2021."},{"issue":"32 Pt A","key":"5608_CR9","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","volume":"36","author":"AR Kreimer","year":"2018","unstructured":"Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32 Pt A):4774\u201382.","journal-title":"Vaccine"},{"key":"5608_CR10","doi-asserted-by":"publisher","unstructured":"Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015;16(7):775\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(15)00047-9.","DOI":"10.1016\/S1470-2045(15)00047-9"},{"key":"5608_CR11","doi-asserted-by":"publisher","unstructured":"Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: the CVT trial. J Natl Cancer Inst. 2018;110(2). https:\/\/doi.org\/10.1093\/jnci\/djx158. PubMed PMID: 28954299","DOI":"10.1093\/jnci\/djx158"},{"issue":"10","key":"5608_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","volume":"112","author":"AR Kreimer","year":"2020","unstructured":"Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020;112(10):1038\u201346. https:\/\/doi.org\/10.1093\/jnci\/djaa011.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"5608_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135563","volume":"10","author":"MM Masika","year":"2015","unstructured":"Masika MM, Ogembo JG, Chabeda SV, Wamai RG, Mugo N. Knowledge on HPV vaccine and cervical cancer facilitates vaccine acceptability among school teachers in Kitui County, Kenya. PLoS One. 2015;10(8):e0135563. https:\/\/doi.org\/10.1371\/journal.pone.0135563.","journal-title":"PLoS One"},{"issue":"1","key":"5608_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-018-4382-x","volume":"18","author":"H Mabeya","year":"2018","unstructured":"Mabeya H, Menon S, Weyers S, Naanyu V, Mwaliko E, Kirop E, et al. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting. BMC Cancer. 2018;18(1):557. https:\/\/doi.org\/10.1186\/s12885-018-4382-x.","journal-title":"BMC Cancer"},{"key":"5608_CR15","unstructured":"Prevention CfDCa. Meningococcal disease 2021 [Available from: https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2020\/travel-related-infectious-diseases\/meningococcal-disease]. Accessed 27 Feb 2021."},{"issue":"3","key":"5608_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5858\/arpa.2015-0117-OA","volume":"140","author":"S Jung","year":"2016","unstructured":"Jung S, Lee B, Lee KN, Kim Y, Oh EJ. Clinical validation of Anyplex II HPV HR detection test for cervical cancer screening in Korea. Arch Pathol Lab Med. 2016;140(3):276\u201380. https:\/\/doi.org\/10.5858\/arpa.2015-0117-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"5608_CR17","doi-asserted-by":"publisher","unstructured":"Hesselink AT, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol. 2014;52(3):890\u20136. https:\/\/doi.org\/10.1128\/JCM.03195-13.","DOI":"10.1128\/JCM.03195-13"},{"key":"5608_CR18","doi-asserted-by":"publisher","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamani J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, Team HS. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595\u2013608. Epub 2021\/08\/12. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","DOI":"10.1056\/NEJMoa2101016"},{"key":"5608_CR19","doi-asserted-by":"publisher","unstructured":"Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM, Hydroxychloroquine C-PEPST. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. Ann Intern Med. 2021;174(3):344-52. Epub 2020\/12\/08. https:\/\/doi.org\/10.7326\/M20-6519.","DOI":"10.7326\/M20-6519"},{"issue":"32 Pt A","key":"5608_CR20","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1016\/j.vaccine.2018.02.023","volume":"36","author":"N Tan","year":"2018","unstructured":"Tan N, Sharma M, Winer R, Galloway D, Rees H, Barnabas RV. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine. 2018;36(32 Pt A):4830\u20136.","journal-title":"Vaccine"},{"key":"5608_CR21","doi-asserted-by":"crossref","unstructured":"Drummond M, Drummond M. Methods for the economic evaluation of health care programmes, 3rd ed: Oxford University Press; 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"5608_CR22","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"issue":"5","key":"5608_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa0904849","volume":"362","author":"C Celum","year":"2010","unstructured":"Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427\u201339. https:\/\/doi.org\/10.1056\/NEJMoa0904849.","journal-title":"N Engl J Med"},{"issue":"22","key":"5608_CR24","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1506110.","journal-title":"N Engl J Med"},{"issue":"5","key":"5608_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524.","journal-title":"N Engl J Med"},{"issue":"5","key":"5608_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533\u20134. https:\/\/doi.org\/10.1016\/S1473-3099(20)30120-1.","journal-title":"Lancet Infect Dis"},{"key":"5608_CR27","unstructured":"Cancer Council Australia. Australia set to eliminate cervical cancer by 2035 2018 [Available from: https:\/\/www.cancer.org.au\/news\/media-releases\/australia-set-to-eliminate-cervical-cancer-by-2035.html]. Accessed 27 Feb 2021."},{"issue":"5","key":"5608_CR28","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386. https:\/\/doi.org\/10.1002\/ijc.29210.","journal-title":"Int J Cancer"},{"key":"5608_CR29","unstructured":"World Health Organization. Cervical Cancer 2018 [Available from: https:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/cervical-cancer\/en\/]. Accessed 27 Feb 2021."},{"key":"5608_CR30","unstructured":"World Health Organization. Monitoring and Surveillance of HPV Vaccination Programmes 2020 [Available from: https:\/\/www.who.int\/immunization\/hpv\/monitor\/en\/]. Accessed 27 Feb 2021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05608-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T07:36:12Z","timestamp":1699515372000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05608-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5608"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05608-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU), in Kenya, and the University of Washington Institutional Review Board, Seattle, WA, approved this study. The study was registered at ClinicalTrials.gov, number NCT03675256.All participants provided written informed consent, which included counseling about randomization, the vaccine used in each study group, strategies for cervical cancer prevention, and their rights as research participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Declaration of interests: RVB reports grants from Bill and Melinda Gates Foundation, grants from National Institutes of Health, grants from Royalty Research Fund (UW), grants from King K. Holmes Professorship in STDs and AIDS, during the conduct of the study; and conference support from Regeneron Pharmaceuticals outside the submitted work. JMB reports grants from Bill & Melinda Gates Foundation during the conduct of the study; grants from BMGF, CDC, NIH, and USAID and personal fees from Gilead Sciences, Merck, and Janssen, outside the submitted work. CC reports grants from BMGF, during the conduct of the study, personal fees from Gilead Sciences, and personal fees from Merck, outside the submitted work. RLW reports grants from NIH and CDC during the conduct of the study. All other co-authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"661"}}